The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Open accessAbstract
Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).Methods Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients. This trial is registered with ClinicalTrials.gov, number NCT00805194.Findings Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a median follow-up of 7·1 months (IQR 3·8-11·0). PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9-3·9] vs 2·7 months [2·6-2·8]; hazard ratio [HR] 0·79 [95% CI 0·68-0·92], p=0·0019). After a median follow-up of 31·7 months (IQR 27·8-36·1), overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10·9 months [95% CI 8·5-12·6] vs 7·9 months [6·7-9·1]; HR 0·75 [95% CI 0·60-0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12·6 months [95% CI 10·6-15·1] vs 10·3 months [95% CI 8·6-12·2]; HR 0·83 [95% CI 0·70-0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 8·8-11·2] vs 9·1 months [8·4-10·4]; HR 0·94, 95% CI 0·83-1·05, p=0·2720). Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in alanine aminotransferase (51 [7·8%] vs six [0·9%]), and reversible increases in aspartate aminotransferase (22 [3·4%] vs three [0·5%]). 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).Interpretation Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma.Funding Boehringer Ingelheim.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with docetaxel, the combination of nintedanib and docetaxel was associated with a higher incidence of gastrointestinal AEs and transient elevation of liver enzymes [102].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Additional unplanned analyses revealed a pronounced impact on OS in patients with fast-progressing disease and patients who were refractory to first-line chemotherapy.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Unfortunately, survival outcomes remain poor and patients often experience substantial toxicity, underscoring a high unmet need. 8 , 9”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Research works printed but not linked: 2
- Hanna, 2013, Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled phase III trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy, Eur J Cancer, 49, 3418
- Reck, 2013, Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy, J Thorac Oncol, 8, O16.01
Cited by
Sorted by citations
Items 801–900 of 952
Antiangiogenic Agents in Lung Cancer: Lost Cause or Flicker of Hope?
Levy, B. P., Lee, J. Y. H., & Becker, D. J. (2015) · American Journal of Hematology / Oncology®
Die medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms
Heigener, D. F., Reinmuth, N., & Reck, M. (2015) · Der Pneumologe · doi:10.1007/s10405-015-0009-y
Self-citationSecond Line in NSCLC: New Opportunities?
Rossi, A., & Galetta, D. (2015) · Lung Cancer Management · doi:10.2217/lmt.14.45
Traitements ciblés et immunothérapie : quel apport en pratique ?
Cortot, A. B. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30015-x
NSCLC: Vorteile für neuen Angiokinasehemmer
Kreutzkamp, B. (2014) · Im Focus Onkologie · doi:10.1007/s15015-014-1268-x
Angiokinase inhibitors in non-small-cell lung cancer
Lu, W., Lin, C.-C., & Yang, J. C. (2015) · Clinical Investigation · doi:10.4155/cli.14.109
Squamous Carcinoma of the Lung: Still a Long and Winding Road to Successful Treatment
Bironzo, P., & Scagliotti, G. V. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.32
Guijarro-Muñoz, I., Roarty, E. B., & Heymach, J. V. (2016) · Cancer · doi:10.1002/cncr.29894
Resistance to anti-angiogenic drugs and therapeutic options
Cappuzzo, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20741-4_6
Perspectives on Nintedanib Treatment in Non-small Cell Lung Cancer
Kaneda, H. (2015) · Haigan · doi:10.2482/haigan.55.962
Carbognin, L., Pilotto, S., Peretti, U., Tortora, G., & Bria, E. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1176140
Anti-angiogenesis therapy for lung cancer: the shore and the other shore ⁎
Zhang, S., Liu, J., Li, H., & Cheng, Y. (2015) · Oncology and Translational Medicine · doi:10.1007/s10330-014-0050-z
Patienten leben länger ohne zusätzliche Nebenwirkungen
Schalhorn, A. (2015) · Info Onkologie · doi:10.1007/s15004-015-0880-z
Common Pathways in IPF and Lung Cancer
Koyama, N. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_14
Reinmuth, N., Reck, M., & Grohé, C. (2014) · Pneumologie · doi:10.1055/s-0034-1390807
Self-citationADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES
Ferrara, G., & Sköld, M. C. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814656337_0012
Achievements in targeted therapies
Bironzo, P., Mele, T., & Novello, S. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010714
Self-citationIndications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors
Vergoulidou, M. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46091-8_7
Blinded Bayesian Adverse Event Monitoring
Sailer, O., & Bailer, T. (2015)
Pérol, M., Paulus, V., & Avrillon, V. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30125-2
Lung Cancer Complicated with Interstitial Lung Diseases
Minegishi, Y. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_15
Anti-Angiogenics in Gastroesophageal Cancer
Hacker, U. T., & Lordick, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-31215-6_17-1
Advancing the Management of Non-small Cell Lung Cancer
Fakih, D. F. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.01.53
Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors
Gray, S. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_36
Analysis of the Efficacy of Apatinib in the Treatment of Brain Metastases of Lung Adenocarcinoma
祝, 金. (2017) · Asian Case Reports in Oncology · doi:10.12677/acrpo.2017.61001
What’s new in chemotherapy for non-small cell lung cancer?
Britschgi, C. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0355-z
Immuntherapie thorakaler Tumoren
Pogorzelski, M., & Eberhardt, W. (2017) · Info Onkologie · doi:10.1007/s15004-017-5789-2
Principles of Cancer Targeted Therapy in Older Adults
Luciani, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-44870-1_16-1
Individualisierte Therapie des metastasierten Lungenkarzinoms
Evers, G., Möhr, M., Kerkhoff, A., Lenz, G., Wiewrodt, R. G., & Schmidt, L. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-103471
Second Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer (NSCLC)
Durm, G. A., & Hanna, N. H. (2017) · Author eBooks
Gauvain, C., & Cortot, A. B. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30057-5
Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors
Hierro, C., & Tabernero, J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00005-6
Learning from the past to design better trials in second-line treatment for mesothelioma patients
Addeo, A., Banna, G. L., & Dietrich, P. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.881
Souquet, P. J. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30035-1
From the Double Helix to Oncogenomics and Precision Cancer Medicine
Dammacco, F., & Silvestris, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00001-6
Paolo, B., Teresa, M., & Silvia, N. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.erm6815
Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer
Ramalingam, S. S., Pillai, R. N., Reinmuth, N., & Reck, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00044-5
Self-citationBakker, E. Y., Guazzelli, A., Demonacos, C., Krstic–Demonacos, M., & Mutti, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812724-7.00010-1
Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC
Rittmeyer, A. (2019) · Wiener klinisches Magazin · doi:10.1007/s00740-019-0279-9
Mechanisms of Lung Carcinogenesis Associated with Interstitial Pneumonia
Honda, T., Miyazaki, Y., & Kohno, T. (2019) · Haigan · doi:10.2482/haigan.59.1134
Zhang, X., Cao, R., Guo, Y., Zhen, Y., Zheng, J., Huang, L., Zhang, S., Jing, W., Sun, L., Zhao, J., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.12.128
[A Review of Drug Therapy of Lung Cancer with Interstitial Lung Disease].
Wang, Y., Zhou, Y., & Miao, L. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.01
Scherpereel, A., Pérol, M., Gauvain, C., Cortot, A. B., & Leprieur, E. G. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30099-9
Реутова, Е. В., Павлович, Л. К., & Сергеевич, А. М. (2017) · Russian Journal of Oncology · doi:10.18821/1028-9984-2017-22-6-300-306
Артамонова, Е. В., & Владимировна, Е. А. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-3-28(403)-18-24
Inmunoterapia en el cáncer de pulmón
Casado, D. I., Bellido, L., del Barco, E., Cigarral, B., Escalera, E., Claros, J., Barrios, B., Figuero, L., Olivares, A., López, Á., et al. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.02.009
Aldaco-Sarvide, F., Valle-Solís, A. A. E., Acosta-Gutiérrez, D. N., Añorve-Bailón, D., Ballesteros-Pino, D. A., Cervantes-Sánchez, G., Cárdenas-Cárdenas, E., Cruz-López, J. C., Díaz-Alvarado, M. G., Durán-Gil, C., et al. (2020) · Latin American Journal of Clinical Sciences and Medical Technology · doi:10.34141/ljcs7299157
Ospina, A. V., Bruges, R. E., Lema, M., Lopes, G. D. L., Jr., Provencio, M., Gómez, R., Lombana, M., Lobatón, J. F., Yepes, A., Abreo, D., et al. (2019) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.11
Suo, J., Sun, Y., Fu, Y., Xiu, W., Zhang, X., Wang, Y., & Zhu, J. (2021) · Research Square · doi:10.21203/rs.3.rs-682548/v1
Tzouvelekis, A., Bouros, D. E., & Karampitsakos, T. (2021) · Barcelona Respiratory Network · doi:10.23866/brnrev:2020-0009
Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable
Pérol, M., Avrillon, V., Zalcman, G., & Scherpereel, A. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00105-1
Cusano, E., Wong, C., Taguedong, E., Vaska, M. M., Abedin, T., Nixon, N. A., Karim, S., Tang, P. A., Heng, D. Y. C., & Ezeife, D. A. (2021) · Current Oncology · doi:10.3390/curroncol28060412
Lungenkarzinom: Mehr Optionen für Patienten im fortgeschrittenen Stadium
Heigener, D. F., & Reck, M. (2017) · Deutsches Ärzteblatt · doi:10.3238/personko/2017.12.01.02
Self-citationIdiopathic Pulmonary Fibrosis Complicated by Adenocarcinoma and Organizing Pneumonia
Inutsuka, Y., Yanagihara, T., Matsumoto, K., Yoneda, R., Hashisako, M., Ogo, N., Asoh, T., & Maeyama, T. (2022) · Cureus · doi:10.7759/cureus.20916
Passiglia, F., Gristina, V., Rolfo, C. D., Barraco, N., Bazan, V., & Russo, A. D. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_32
Anti-angiogenics in Gastroesophageal Cancer
Hacker, U. T., & Lordick, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_17
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., & Nilsson, M. B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017
Greystoke, A. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.04.006
Baldacci, S., & Cortot, A. B. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30037-9
Baldacci, S., & Cortot, A. B. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30074-4
Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors
Gray, S. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_36-1
Mecca, C., Bertaglia, V., & Novello, S. (2019) · Translational Cancer Research · doi:10.21037/tcr.2018.08.23
Self-citationPrinciples of Cancer Targeted Therapy in Older Adults
Luciani, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_16
Malignome des Respirationstrakts
Schmittel, A. H. (2017) · Elsevier eBooks · doi:10.1016/b978-3-437-21214-7.00015-8
Schirripa, M., Lenz, H., & Scherer, S. J. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_17-4
Nicht-kleinzelliges Bronchialkarzinom
Schill, C., Bubendorf, L., Papachristofilou, A., Grendelmeier, P. S., Lardinois, D., Bremerich, J., Zippelius, A., & Rothschild, S. I. (2015) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2015.02276
Malignome des Respirationstrakts
Schmittel, A. H. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-21215-4.00015-9
Zhao, H., Li, R., Wang, X., Lu, X., Hu, M., Zhang, J., Zhao, X., Song, X., & Liu, Y. (2020) · Research Square · doi:10.21203/rs.3.rs-22091/v2
Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer
Maïo, M. D., Novello, S., Capelletto, E., & Scagliotti, G. V. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_22
Self-citationSchirripa, M., Lenz, H., & Scherer, S. J. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_17
Zhao, H., Li, R., Wang, X., Lu, X., Hu, M., Zhang, J., Zhao, X., Song, X., & Liu, Y. (2020) · Research Square · doi:10.21203/rs.3.rs-22091/v1
Tumor-Vascular Interactions in Non-Small Cell Lung Cancer
Ramnefjell, M., & Akslen, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_29
Substanzen gegen molekulare Zielstrukturen
Zirlik, K., & Duyster, J. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_369-1
Sequenz, Kombinationen, frühe Stadien - alles rund um die Immuntherapie
Hammerschmidt, S., & Geßner, C. (2022) · Pneumo News · doi:10.1007/s15033-022-2855-8
Algorithme thérapeutique des CBNPC sans mutation addictive
Cortot, A. B., Pérol, M., Avrillon, V., & Zalcman, G. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00117-3
State of the Art: nicht onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV
Neise, S., & Reck, M. (2022) · Die Onkologie · doi:10.1007/s00761-022-01247-z
Self-citationFibrose pulmonaire et cancer pulmonaire : entre complémentarités et spécificités
Cobo, J. R., Vraka, A., Mansouri, N., & Messea, R. (2022) · JMIG · doi:10.53738/revmed.2022.18.804.2162
Teodorescu, M., & Grigorescu, A. C. (2022) · Oncolog-Hematolog ro · doi:10.26416/onhe.60.3.2022.7154
Teixeira, A. R., Fernandes, R., & Rodrigues, A. (2023) · Cureus · doi:10.7759/cureus.33577
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_5
Sun, M.-G., Park, S. J., Kim, Y. J., Moon, K., Kim, I., Jung, S., Oh, H., Oh, I., & Jung, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134307
Zhang, L., Wang, P., Mo, Y., Zhang, Y., Tong, X., Zhang, X., & Li, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3171136/v1
Atagi, S., Daimon, T., Okishio, K., Komuta, K., Okano, Y., Minato, K., Kim, Y. H., Usui, R., Tabata, C., Tamura, A., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15080
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Pacheco-Barcía, V., Palka-Kotlowska, M., Saez-Bertrand, C., & Blasco-Guerrero, M. (2023) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.5.077
Fujiwara, K., Tsuji, A. B., Sudo, H., Sugyo, A., Hamakubo, T., & Higashi, T. (2023) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001775
Algorithme thérapeutique des CBNPC sans mutation addictive
Mazières, J., Pérol, M., & Cortot, A. B. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00141-6
Leprieur, E. G., Scherpereel, A., Pérol, M., Gauvain, C., & Cortot, A. B. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00142-8
Zlatanova, T., & Arabadjiev, J. I. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e111820
Taguchi, Y., Hirayama, R., Katayama, I., Yamamoto, H., Nagai, A., Ueda, S., Hirose, M., Sugimoto, E., Nakamura, Y. A., & Yamaguchi, O. (2023) · Haigan · doi:10.2482/haigan.63.946
Trigo, J. M. (2024) · Revisiones en cáncer · doi:10.20960/revcancer.00052
Malignome des Respirationstrakts
Schmittel, A. H. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21207-9.00015-x
Liquid Biopsy in non-small cell lung cancer: exosomes as a tool for the study of biomarkers.
Sáez, M. E. D. (2024) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/203438
History Can Teach Us Something: Angiogenesis Inhibition Revisited
Eberhardt, W., & Sebastian, M. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.02.008
Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications
Bhatia, A., Sobti, R. C., & Sharma, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-6263-1_20
Algorithme thérapeutique des CBNPC sans mutation addictive
Moro‐Sibilot, D., Mazières, J., Berardi, G., Pérol, M., & Cortot, A. B. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00089-2
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_5
Fibroblast Growth Factor Receptor Inhibitors and Their Application in Non-Small Cell Lung Cancer
Shi, Z. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.22549
Kato, Y., Ogawa, T., Sato, K., Matsukida, A., Kawana, A., Nagaoka, R., Esaki, K., & Kimizuka, Y. (2025) · Respirology Case Reports · doi:10.1002/rcr2.70241
Navigating the Alphabet Soup of Interstitial Lung Diseases ( ILD ): The Role of Pharmacists
Martirosov, A. L., Abdalla, M., Fleischman, M. E., Foster, B., Gonzales, J. P., Lipari, M., Malesker, M. A., Smith, Z., Wilken, L. A., & Williams, D. M. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70089
Metadata
- Authors
- Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Gann, C.-N., Barrueco, J., Gaschler-Markefski, B., & Novello, S.
- Affiliations
- German Center for Lung Research (DE)
- Boehringer Ingelheim (Germany) (DE)
- Herlev Hospital (DK)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Meir Medical Center (IL)
- Dnipro State Medical University (UA)
- Shanghai Jiao Tong University (CN)
- Boehringer Ingelheim (United States) (US)
- University of Turin (IT)
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 15
- Issue
- 2
- Pages
- 143-155
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2170030318
- Cited by
- 951
- References
- 36
- Citations by year
- 2026: 35 · 2025: 41 · 2024: 64 · 2023: 67 · 2022: 74 · 2021: 67 · 2020: 72 · 2019: 83 · 2018: 81 · 2017: 117 · 2016: 103 · 2015: 102 · 2014: 45
- FWCI
- 98.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, docetaxel, nintedanib, second-line therapy, progression-free survival, overall survival, tyrosine kinase inhibitors, EGFR inhibitors, bevacizumab, brain metastases, adenocarcinoma, targeted therapy, combination chemotherapy, drug safety and tolerability
- MeSH terms
- Docetaxel, Adenocarcinoma of Lung, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Europe, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Risk Factors, South Africa, Time Factors, Proportional Hazards Models, Odds Ratio, Treatment Outcome, Disease Progression, Disease-Free Survival, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
